A randomised mulitcentre trial of tenofovir (TDF) vs lamividine (LAM) vs TDF/LAM in antiretroviral naive subjects with HIV/HBV conifection over 48 weeks.

Trial Profile

A randomised mulitcentre trial of tenofovir (TDF) vs lamividine (LAM) vs TDF/LAM in antiretroviral naive subjects with HIV/HBV conifection over 48 weeks.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Tenofovir (Primary) ; Lamivudine
  • Indications Hepatitis B; HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms TICO
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 14 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top